Androgen receptor splice variant AR3 promotes prostate cancer via modulating expression of autocrine/paracrine factors

Journal of Biological Chemistry

Volumn 289, Issue 3, 2014, Pages 1529-1539

  Sun, Feng ^a   Chen, He Ge ^a   Li, Wei ^a   Yang, Xi ^a   Wang, Xin ^a   Jiang, Richeng ^a   Guo, Zhiyong ^a   Chen, Hegang ^a   Huang, Jiaoti ^b   Borowsky, Alexander D ^c   Qiu, Yun ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTORS; CONSTITUTIVELY ACTIVES; DIFFERENTIATION PROCESS; INTERMEDIATE CELLS; PROGENITOR CELL; PROSTATE CANCERS; SPLICE VARIANTS; TRANSGENIC MICE;

CELL CULTURE; CELL PROLIFERATION; TUMORS; UROLOGY;

DISEASES;

ANDROGEN RECEPTOR; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA2; AR PROTEIN, HUMAN; ISOPROTEIN; SIGNAL PEPTIDE; TUMOR PROTEIN;

ADULT; ALTERNATIVE RNA SPLICING; ANDROGEN THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AR3 TRANSGENE; ARTICLE; CANCER STEM CELL; CELL POPULATION; CONTROLLED STUDY; DISEASE COURSE; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MALE; MOUSE; NEWBORN; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; SIGNAL TRANSDUCTION; TISSUE REGENERATION; TRANSGENE; UPREGULATION; ANIMAL; AUTOCRINE EFFECT; BIOSYNTHESIS; EXPERIMENTAL NEOPLASM; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PARACRINE SIGNALING; PATHOLOGY; PROSTATE TUMOR; SECRETION (PROCESS); TRANSGENIC MOUSE; TUMOR CELL LINE;

ALTERNATIVE SPLICING; ANIMALS; AUTOCRINE COMMUNICATION; CELL LINE, TUMOR; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICE; MICE, TRANSGENIC; NEOPLASM PROTEINS; NEOPLASMS, EXPERIMENTAL; PARACRINE COMMUNICATION; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS; RECEPTORS, ANDROGEN; UP-REGULATION;

EID: 84892645101     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.492140     Document Type: Article

References (61)

1. Heinlein, C. A., and Chang, C. (2004) Androgen receptor in prostate cancer. Endocr. Rev. 25, 276-308 (Pubitemid 38501396)
2. Bolton, E. C., So, A. Y., Chaivorapol, C., Haqq, C. M., Li, H., and Yamamoto, K. R. (2007) Cell- and gene-specific regulation of primary target genes by the androgen receptor. Genes Dev. 21, 2005-2017 (Pubitemid 47267287)
3. Wang, Q., Li, W., Liu, X. S., Carroll, J. S., Jänne, O. A., Keeton, E. K., Chinnaiyan, A. M., Pienta, K. J., and Brown, M. (2007) A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol. Cell 27, 380-392 (Pubitemid 47126935)
4. Narayanan, R., Jiang, J., Gusev, Y., Jones, A., Kearbey, J. D., Miller, D. D., Schmittgen, T. D., and Dalton, J. T. (2010) MicroRNAs are mediators of androgen action in prostate and muscle. PLoS One 5, e13637
5. Takayama, K., Tsutsumi, S., Katayama, S., Okayama, T., Horie-Inoue, K., Ikeda, K., Urano, T., Kawazu, C., Hasegawa, A., Ikeo, K., Gojyobori, T., Ouchi, Y., Hayashizaki, Y., Aburatani, H., and Inoue, S. (2011) Integration of cap analysis of gene expression and chromatin immunoprecipitation analysis on array reveals genome-wide androgen receptor signaling in prostate cancer cells. Oncogene 30, 619-630
6. Dai, B., Chen, H., Guo, S., Yang, X., Linn, D. E., Sun, F., Li, W., Guo, Z., Xu, K., Kim, O., Kong, X., Melamed, J., Qiu, S., and Qiu, Y. (2010) Compensatory up-regulation of tyrosine kinase Etk/BMX in response to androgen deprivation promotes castration-resistant growth of prostate cancer cells. Cancer Res. 70, 5587-5596
7. Guo, Z., Dai, B., Jiang, T., Xu, K., Xie, Y., Kim, O., Nesheiwat, I., Kong, X., Melamed, J., Handratta, V. D., Njar, V. C., Brodie, A. M., Yu, L. R., Veenstra, T. D., Chen, H., and Qiu, Y. (2006) Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell 10, 309-319 (Pubitemid 44512189)
8. Mahajan, N. P., Liu, Y., Majumder, S., Warren, M. R., Parker, C. E., Mohler, J. L., Earp, H. S., and Whang, Y. E. (2007) Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation. Proc. Natl. Acad. Sci. U.S.A. 104, 8438-8443 (Pubitemid 47175506)
9. DaSilva, J., Gioeli, D., Weber, M. J., and Parsons, S. J. (2009) The neuroendocrine-derived peptide parathyroid hormone-related protein promotes prostate cancer cell growth by stabilizing the androgen receptor. Cancer Res. 69, 7402-7411
10. Dehm, S. M., Schmidt, L. J., Heemers, H. V., Vessella, R. L., and Tindall, D. J. (2008) Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res. 68, 5469-5477
11. Guo, Z., Yang, X., Sun, F., Jiang, R., Linn, D. E., Chen, H., Kong, X., Melamed, J., Tepper, C. G., Kung, H. J., Brodie, A. M., Edwards, J., and Qiu, Y. (2009) A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res. 69, 2305-2313
12. Hu, R., Dunn, T. A., Wei, S., Isharwal, S., Veltri, R. W., Humphreys, E., Han, M., Partin, A. W., Vessella, R. L., Isaacs, W. B., Bova, G. S., and Luo, J. (2009) Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 69, 16-22
13. Sun, S., Sprenger, C. C., Vessella, R. L., Haugk, K., Soriano, K., Mostaghel, E. A., Page, S. T., Coleman, I. M., Nguyen, H. M., Sun, H., Nelson, P. S., and Plymate, S. R. (2010) Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J. Clin. Invest. 120, 2715-2730
14. Shen, M. M., and Abate-Shen, C. (2010) Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev. 24, 1967-2000
15. Scher, H. I., Buchanan, G., Gerald, W., Butler, L. M., and Tilley, W. D. (2004) Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocr. Relat. Cancer 11, 459-476 (Pubitemid 39331277)
16. Scher, H. I., and Sawyers, C. L. (2005) Biology of progressive, castrationresistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J. Clin. Oncol. 23, 8253-8261 (Pubitemid 46211563)
17. Niu, Y., Chang, T. M., Yeh, S., Ma, W. L., Wang, Y. Z., and Chang, C. (2010) Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails. Oncogene 29, 3593-3604
18. Lawson, D. A., Xin, L., Lukacs, R. U., Cheng, D., and Witte, O. N. (2007) Isolation and functional characterization of murine prostate stem cells. Proc. Natl. Acad. Sci. U.S.A. 104, 181-186 (Pubitemid 46068005)
19. Leong, K. G., Wang, B. E., Johnson, L., and Gao, W. Q. (2008) Generation of a prostate from a single adult stem cell. Nature 456, 804-808
20. Xin, L., Lawson, D. A., and Witte, O. N. (2005) The Sca-1 cell surface marker enriches for a prostate-regenerating cell subpopulation that can initiate prostate tumorigenesis. Proc. Natl. Acad. Sci. U.S.A. 102, 6942-6947 (Pubitemid 40675421)
21. Goldstein, A. S., Huang, J., Guo, C., Garraway, I. P., and Witte, O. N. (2010) Identification of a cell of origin for human prostate cancer. Science 329, 568-571
22. Mulholland, D. J., Xin, L., Morim, A., Lawson, D., Witte, O., and Wu, H. (2009) Lin-Sca-1+CD49fhigh stem/progenitors are tumor-initiating cells in the Pten-null prostate cancer model. Cancer Res. 69, 8555-8562
23. Wang, X., Kruithof-de Julio, M., Economides, K. D., Walker, D., Yu, H., Halili, M. V., Hu, Y. P., Price, S. M., Abate-Shen, C., and Shen, M. M. (2009) A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature 461, 495-500
24. Hayward, S. W., Haughney, P. C., Rosen, M. A., Greulich, K. M., Weier, H. U., Dahiya, R., and Cunha, G. R. (1998) Interactions between adult human prostatic epithelium and rat urogenital sinus mesenchyme in a tissue recombination model. Differentiation 63, 131-140 (Pubitemid 28362377)
25. Thomson, A. A., and Cunha, G. R. (1999) Prostatic growth and development are regulated by FGF10. Development 126, 3693-3701 (Pubitemid 29419524)
26. Hörnberg, E., Ylitalo, E. B., Crnalic, S., Antti, H., Stattin, P., Widmark, A., Bergh, A., and Wikström, P. (2011) Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration resistance and short survival. PLoS One 6, e19059
27. Guo, Z., and Qiu, Y. (2011) A new trick of an old molecule: androgen receptor splice variants taking the stage. Int. J. Biol. Sci. 7, 815-822
28. Dai, B., Kim, O., Xie, Y., Guo, Z., Xu, K., Wang, B., Kong, X., Melamed, J., Chen, H., Bieberich, C. J., Borowsky, A. D., Kung, H. J., Wei, G., Ostrowski, M. C., Brodie, A., and Qiu, Y. (2006) Tyrosine kinase Etk/BMX is upregulated in human prostate cancer and its overexpression induces prostate intraepithelial neoplasia in mouse. Cancer Res. 66, 8058-8064 (Pubitemid 44299171)
29. Xin, L., Lukacs, R. U., Lawson, D. A., Cheng, D., and Witte, O. N. (2007) Self-renewal and multilineage differentiation in vitro from murine prostate stem cells. Stem Cells 25, 2760-2769 (Pubitemid 350127860)
30. Gregory, C. W., Johnson, R. T., Jr., Mohler, J. L., French, F. S., and Wilson, E. M. (2001) Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res. 61, 2892-2898 (Pubitemid 32691931)
31. Guo, S., Sun, F., Guo, Z., Li, W., Alfano, A., Chen, H., Magyar, C. E., Huang, J., Chai, T. C., Qiu, S., and Qiu, Y. (2011) Tyrosine kinase ETK/BMX is up-regulated in bladder cancer and predicts poor prognosis in patients with cystectomy. PLoS One 6, e17778
32. Wu, X., Wu, J., Huang, J., Powell, W. C., Zhang, J., Matusik, R. J., Sangiorgi, F. O., Maxson, R. E., Sucov, H. M., and Roy-Burman, P. (2001) Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissuespecific gene ablation. Mech. Dev. 101, 61-69 (Pubitemid 32186310)
33. Zhang, J., Thomas, T. Z., Kasper, S., and Matusik, R. J. (2000) A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo in vivo. Endocrinology 141, 4698-4710 (Pubitemid 32055150)
34. Goldstein, A. S., Lawson, D. A., Cheng, D., Sun, W., Garraway, I. P., and Witte, O. N. (2008) Trop2 identifies a subpopulation of murine and human prostate basal cells with stem cell characteristics. Proc. Natl. Acad. Sci. U.S.A. 105, 20882-20887
35. Signoretti, S., Waltregny, D., Dilks, J., Isaac, B., Lin, D., Garraway, L., Yang, A., Montironi, R., McKeon, F., and Loda, M. (2000) p63 is a prostate basal cell marker and is required for prostate development. Am. J. Pathol. 157, 1769-1775
36. Wang, S., Garcia, A. J., Wu, M., Lawson, D. A., Witte, O. N., and Wu, H. (2006) Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation. Proc. Natl. Acad. Sci. U.S.A. 103, 1480-1485 (Pubitemid 43191191)
37. James, D., Levine, A. J., Besser, D., and Hemmati-Brivanlou, A. (2005) TGFβ/activin/nodal signaling is necessary for the maintenance of pluripotency in human embryonic stem cells. Development 132, 1273-1282 (Pubitemid 40528787)
38. Salm, S. N., Burger, P. E., Coetzee, S., Goto, K., Moscatelli, D., and Wilson, E. L. (2005) TGF-β maintains dormancy of prostatic stem cells in the proximal region of ducts. J. Cell Biol. 170, 81-90 (Pubitemid 40994098)
39. Blum, R., Gupta, R., Burger, P. E., Ontiveros, C. S., Salm, S. N., Xiong, X., Kamb, A., Wesche, H., Marshall, L., Cutler, G., Wang, X., Zavadil, J., Moscatelli, D., and Wilson, E. L. (2009) Molecular signatures of prostate stem cells reveal novel signaling pathways and provide insights into prostate cancer. PLoS One 4, e5722
40. Maragkakis, M., Alexiou, P., Papadopoulos, G. L., Reczko, M., Dalamagas, T., Giannopoulos, G., Goumas, G., Koukis, E., Kourtis, K., Simossis, V. A., Sethupathy, P., Vergoulis, T., Koziris, N., Sellis, T., Tsanakas, P., and Hatzigeorgiou, A. G. (2009) Accurate microRNA target prediction correlates with protein repression levels. BMC Bioinformatics 10, 295
41. Maragkakis, M., Reczko, M., Simossis, V. A., Alexiou, P., Papadopoulos, G. L., Dalamagas, T., Giannopoulos, G., Goumas, G., Koukis, E., Kourtis, K., Vergoulis, T., Koziris, N., Sellis, T., Tsanakas, P., and Hatzigeorgiou, A. G. (2009) DIANA-microT web server: elucidating microRNA functions through target prediction. Nucleic Acids Res. 37, W273-276
42. Fabbri, M., Garzon, R., Cimmino, A., Liu, Z., Zanesi, N., Callegari, E., Liu, S., Alder, H., Costinean, S., Fernandez-Cymering, C., Volinia, S., Guler, G., Morrison, C. D., Chan, K. K., Marcucci, G., Calin, G. A., Huebner, K., and Croce, C. M. (2007) MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc. Natl. Acad. Sci. U.S.A. 104, 15805-15810 (Pubitemid 350035380)
43. DiGiovanni, J., Kiguchi, K., Frijhoff, A., Wilker, E., Bol, D. K., Beltrán, L., Moats, S., Ramirez, A., Jorcano, J., and Conti, C. (2000) Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 97, 3455-3460 (Pubitemid 30183324)
44. Tanaka, H., Kono, E., Tran, C. P., Miyazaki, H., Yamashiro, J., Shimomura, T., Fazli, L., Wada, R., Huang, J., Vessella, R. L., An, J., Horvath, S., Gleave, M., Rettig, M. B., Wainberg, Z. A., and Reiter, R. E. (2010) Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance. Nat. Med. 16, 1414-1420
45. Stanbrough, M., Leav, I., Kwan, P. W., Bubley, G. J., and Balk, S. P. (2001) Prostatic intraepithelial neoplasia in mice expressing an androgen receptor transgene in prostate epithelium. Proc. Natl. Acad. Sci. U.S.A. 98, 10823-10828 (Pubitemid 32878704)
46. Han, G., Buchanan, G., Ittmann, M., Harris, J. M., Yu, X., Demayo, F. J., Tilley, W., and Greenberg, N. M. (2005) Mutation of the androgen receptor causes oncogenic transformation of the prostate. Proc. Natl. Acad. Sci. U.S.A. 102, 1151-1156 (Pubitemid 40170741)
47. Wu, C. T., Altuwaijri, S., Ricke, W. A., Huang, S. P., Yeh, S., Zhang, C., Niu, Y., Tsai, M. Y., and Chang, C. (2007) Increased prostate cell proliferation and loss of cell differentiation in mice lacking prostate epithelial androgen receptor. Proc. Natl. Acad. Sci. U.S.A. 104, 12679-12684 (Pubitemid 47255214)
48. Porkka, K. P., Pfeiffer, M. J., Waltering, K. K., Vessella, R. L., Tammela, T. L., and Visakorpi, T. (2007) MicroRNA expression profiling in prostate cancer. Cancer Res. 67, 6130-6135 (Pubitemid 47037493)
49. Ozen, M., Creighton, C. J., Ozdemir, M., and Ittmann, M. (2008) Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 27, 1788-1793 (Pubitemid 351380263)
50. Mantzoros, C. S., Tzonou, A., Signorello, L. B., Stampfer, M., Trichopoulos, D., and Adami, H. O. (1997) Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br. J. Cancer 76, 1115-1118 (Pubitemid 27448004)
51. Wolk, A., Mantzoros, C. S., Andersson, S. O., Bergström, R., Signorello, L. B., Lagiou, P., Adami, H. O., and Trichopoulos, D. (1998) Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J. Natl. Cancer Inst. 90, 911-915 (Pubitemid 28304159)
52. Chan, J. M., Stampfer, M. J., Giovannucci, E., Gann, P. H., Ma, J., Wilkinson, P., Hennekens, C. H., and Pollak, M. (1998) Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279, 563-566 (Pubitemid 28067285)
53. Harman, S. M., Metter, E. J., Blackman, M. R., Landis, P. K., and Carter, H. B. (2000) Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer. J. Clin. Endocrinol. Metab. 85, 4258-4265 (Pubitemid 32055383)
54. Chokkalingam, A. P., Pollak, M., Fillmore, C. M., Gao, Y. T., Stanczyk, F. Z., Deng, J., Sesterhenn, I. A., Mostofi, F. K., Fears, T. R., Madigan, M. P., Ziegler, R. G., Fraumeni, J. F., Jr., and Hsing, A. W. (2001) Insulin-like growth factors and prostate cancer: a population-based case-control study in China. Cancer Epidemiol. Biomarkers Prev. 10, 421-427 (Pubitemid 32701626)
55. Perry, K. T., Anthony, C. T., and Steiner, M. S. (1997) Immunohistochemical localization of TGFβ1, TGFβ2, and TGFβ3 in normal and malignant human prostate. Prostate 33, 133-140 (Pubitemid 27415537)
56. Ao, M., Williams, K., Bhowmick, N. A., and Hayward, S. W. (2006) Transforming growth factor-β promotes invasion in tumorigenic but not in nontumorigenic human prostatic epithelial cells. Cancer Res. 66, 8007-8016 (Pubitemid 44299165)
57. Niu, Y., Altuwaijri, S., Lai, K. P., Wu, C. T., Ricke, W. A., Messing, E. M., Yao, J., Yeh, S., and Chang, C. (2008) Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proc. Natl. Acad. Sci. U.S.A. 105, 12182-12187
58. Watson, P. A., Chen, Y. F., Balbas, M. D., Wongvipat, J., Socci, N. D., Viale, A., Kim, K., and Sawyers, C. L. (2010) Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc. Natl. Acad. Sci. U.S.A. 107, 16759-16765
59. Yamashita, S., Lai, K. P., Chuang, K. L., Xu, D., Miyamoto, H., Tochigi, T., Pang, S. T., Li, L., Arai, Y., Kung, H. J., Yeh, S., and Chang, C. (2012) ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors. Neoplasia 14, 74-83
60. Tsai, H. C., Boucher, D. L., Martinez, A., Tepper, C. G., and Kung, H. J. (2012) Modeling truncated AR expression in a natural androgen-responsive environment and identification of RHOB as a direct transcriptional target. PLoS One 7, e49887
61. Lin, T. H., Lee, S. O., Niu, Y., Xu, D., Liang, L., Li, L., Yeh, S. D., Fujimoto, N., Yeh, S., and Chang, C. (2013) Differential androgen deprivation therapies with anti-androgens of Casodex or MDV3100 vs. anti-androgen receptor of ASC-J9 lead to promote vs. suppress prostate cancer metastasis. J. Biol. Chem. 288, 19359-19369